Forian Q2 Revenue Jumps 56 Percent

Forian (NASDAQ:FORA) reported robust Q2 2025 results, with GAAP revenue increasing 56% year-over-year to $7.5 million and net income reaching $224,000, reversing a prior-year loss. Adjusted EBITDA significantly improved to $591,000, primarily driven by the October 2024 Kyber Data Science acquisition and ongoing cost optimizations. Management reaffirmed full-year 2025 revenue guidance of $28 million to $30 million and adjusted EBITDA guidance between negative $1 million and positive $1 million, citing confidence from a strong contracted backlog and multiyear life sciences licenses. The company continues to leverage its proprietary data assets for competitive advantage and actively pursues strategic acquisitions, supported by $35.6 million in liquidity.

Analysis

Forian reported a strong second quarter for 2025, demonstrating significant operational momentum and a successful strategic pivot towards profitability. The company's GAAP revenue grew 56% year-over-year to $7.5 million, while it reversed a prior-year loss of $2.5 million to achieve a net income of $224,000. This turnaround is primarily attributed to the accretive acquisition of Kyber Data Science in October 2024, which contributed $1.9 million in incremental revenue, and the realization of cost optimizations. The impact on margins was substantial, with adjusted EBITDA increasing to $591,000 from $78,000 in the prior-year period. Management reaffirmed its full-year 2025 revenue guidance of $28 million to $30 million, citing high visibility from its contracted backlog and renewal pipeline. The company's balance sheet appears robust, with $35.6 million in cash and marketable securities against a $6.8 million convertible note maturing in September 2025, positioning it well to execute on its active M&A strategy.

Key Decisions for Investors

• Given the strong revenue growth, margin expansion, and reaffirmed guidance, investors may view the current results as validation of the company's M&A and operational strategy.
• The successful closure of scheduled renewals in the second half of the year is a critical dependency for meeting full-year guidance, representing the primary risk factor to monitor.
• With $35.6 million in liquidity and an active M&A focus, investors should watch for potential acquisition announcements, which could serve as a significant catalyst for future growth.
• The upcoming maturity of the $6.8 million convertible note in September 2025 is a key event; its successful retirement will remove a near-term financial overhang and further de-risk the balance sheet.